Compare KLA Corp. (KLAC) vs Pfizer Inc (PFE) Price & Performance

KLA Corporation (KLAC) trades at $196.72, showing slight daily weakness but maintaining a strong uptrend supported by bullish technical indicators and robust fundamentals. The company reported revenue of $12.16 billion in 2025 with a net income margin of 35.57%, and has consistently beaten earnings expectations in recent quarters. AI-driven demand is fueling growth, with a backlog of $12.57 billion highlighting strong future revenue visibility.

The outlook for KLAC remains positive, driven by semiconductor equipment demand from AI and advanced packaging. Key opportunities include market leadership in inspection and metrology, while risks involve competitive pressures from Applied Materials and ASML, and execution challenges in scaling operations. The consensus price target of $223.88 suggests significant upside potential from current levels.

Pfizer (PFE) trades at $27.82, down 0.64% on the day, with a bullish technical signal from moving averages and oversold RSI levels. The company reported revenue of $62.58B in 2025 with a net income margin of 6.8%, and has beaten earnings estimates for three consecutive quarters. Recent news highlights Pfizer's focus on its obesity and oncology pipeline, positioning for a catalyst-rich 2026.

The stock presents a value opportunity with a forward P/E of 36.61 and consensus price target of $29.17, but faces risks from patent cliffs and volatile cash flows. Analyst sentiment is mixed with 40% buy ratings, while institutional outlook remains cautious amid earnings pressure and competitive threats in the pharma sector.